Neurogene (NGNE) Common Equity (2013 - 2026)

Neurogene (NGNE) has 14 years of Common Equity data on file, last reported at $237.8 million in Q1 2026.

• Quarterly Common Equity fell 18.51% year-over-year to $237.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $237.8 million (down 18.51% YoY) and the FY2025 annual result came in at $264.9 million, down 14.66% from the prior year.
• Common Equity retreated to $237.8 million in Q1 2026, from $264.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $310.4 million in Q4 2024 to a low of -$183.2 million in Q3 2023.
• A 5-year average of $117.0 million and a median of $155.0 million in 2024 frame the typical range for Common Equity.
• The widest YoY moves for Common Equity: up 227.64% in 2023, down 273.42% in 2023.
• Tracing NGNE's Common Equity over 5 years: stood at -$145.7 million in 2022, then soared by 227.64% to $186.0 million in 2023, then surged by 66.85% to $310.4 million in 2024, then dropped by 14.66% to $264.9 million in 2025, then fell by 10.23% to $237.8 million in 2026.
• The last three Common Equity figures came in at $237.8 million (Q1 2026), $264.9 million (Q4 2025), and $265.5 million (Q3 2025), per Business Quant data.